The treatment that a patient is given can impact on the course of their pain and disability. It can be difficult to determine what treatment method will be most effective for a particular case and these need to be assessed both from a medical and a psychological perspective. Although some rare conditions may respond to specific treatments there is no single way of managing the range of causes of pain.
About 14 million US adults a year are diagnosed with peripheral nervous system (PNS) disorders. This accounts for 22% of American adults with a diagnosis.
While some evidence of a strong genetic component exists for some peripheral nerve diseases, the mechanisms by which genes modify the risk of these disorders are not clear. Some environmental toxins, such as asbestos and cigarette smoke, may cause some peripheral nervous system diseases. The effect of environmental factors on peripheral nervous system diseases may differ across the types of disease, and may in part explain why individuals with certain diseases may be predisposed to developing another disease in the future. The risk of developing peripheral nervous system diseases seems to be positively associated with age, which may be a result of environmental changes that accumulate with age.
Current therapies for peripheral neuropathies are limited. The best options are often based on the type of lesion, as well as patient preferences and available expertise. This article presents a summary of the treatment approaches for peripheral neuropathies.
PNS disorders are common and constitute a major cause of disability. They are potentially disabling and can sometimes interfere with the patient's daily activity or even lead to death. Moreover, they are treated mainly by physical therapy, with or without medications, which are usually expensive and less effective or well tolerated, although in recent years medications are sometimes prescribed to provide rapid symptom control. This issue is not being emphasized by health professionals during patient follow-up. Finally, current neurologic practices have no standardized documentation or management. A proper assessment of peripheral nervous system disorders based on a careful medical history and physical examination by a competent professional is the cornerstone of a successful clinical management.
Nerves of the PNS are involved in the disease and they can be affected on different levels, from the skin manifestations (which give information about the localisation) to the peripheral and central nervous involvement and in most cases there is no pain, therefore no symptom. PN may also affect other PN or SNS.
Findings from a recent study of this study should assist users and caregivers who are not only interested but also concerned about choosing a proper athletic sock for athletes. The design of the voxx sock should aim at the control of the heat and moisture loss, the prevention of the skin from drying out and the overall comfort of the foot.
Sock devices do not improve exercise performance and are associated with a higher incidence of adverse health effects. There are no indications to suggest that Voxx garments influence recovery from exercise or the incidence of adverse health effects.
The study showed that only a small minority of patients with PNSDs consider participating in clinical trials, and there would be no benefit for all. Patients and families with PNSDs should be aware that they are likely to feel more uncomfortable and more pressure in clinical trials, but there will be no benefit for most patients on clinical trials.
While familial SPG, SPS, and neuropathy are all autosomal dominant conditions, SPG, SPS, and CMT type 1A are all multifactorial conditions due to the different genes and environmental factors responsible for each condition. SSP and CMT type 2a are both multifactorial as well, but more so than other spastic paraplegia types. There are no families with a combination of SSP, SPS, and CMT type 2a. Spastic paraplegia family history has been reported in the medical literature for at least two decades, but it is still not recognized as a clinical concept.
Results of this study show that use of the Vita VF-VX3 Vx-M socks is safe for people. The study also shows that some people are not satisfied in using the socks. Implication for practice Recent findings shows that use of the Vita VF-VX3® socks by people is safe. However, it is recommended that further studies are needed in order to improve user satisfaction about sock use.
PNS diseases (peripheral neuropathies) are more common among individuals older than 60 years of age. This is an observation which should make clinicians more cautious when treating these patients because of the likelihood of more complicated or delayed diagnoses with increasing age and may ultimately lead patients to more urgent interventions such as surgery or biopsy when the disease is already in a life threatening state.